EHA

SNMMI 2023 Annual Meeting Abstract of the Year Awarded to Actinium's Iomab-B Phase 3 SIERRA Data

Retrieved on: 
Monday, June 26, 2023
Actinium, EBMT, Society of Nuclear Medicine and Molecular Imaging, Society, SNMMI, Nursing, Safety, Molecular imaging, Survival, Food and Drug Administration, Radiology, Prognosis, HCT, American Cancer Society, TCT, Nuclear medicine, AML, MD, Patient, Memorial Sloan Kettering Cancer Center, EHA, Annual general meeting, Growth, Leukemia, Abstract, BLA, NYSE, Weill Cornell Medicine, Food, Disease, Pharmaceutical industry, Medical imaging

NEW YORK, June 26, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM, 'Actinium'), a leader in the development of targeted radiotherapies, today announced that the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting selected Abstract 685 titled "Individualized dosing for high-dose targeted radiation of hematopoietic cells with Iomab-B (I131-apamistamab) prior to HCT in relapsed/refractory acute myeloid leukemia (R/R AML): Safety and efficacy results from the pivotal phase 3 SIERRA trial" as the Abstract of the Year.

Key Points: 
  • "It is a great honor for this SIERRA data abstract and this team of esteemed abstract authors to have received this award highlighting Iomab-B's potential for people with relapsed and refractory AML," said Sandesh Seth, Chairman and Chief Executive Officer.
  • "Today's SNMMI honor represents the fourth oral presentation of the SIERRA trial data at prestigious medical conferences in 2023, including TCT, EBMT, and EHA.
  • This will add further growth and impetus to use of nuclear medicine in planning and administration of theranostic radioimmunotargeted therapy."
  • The American Cancer Society estimates that 20,380 people will be diagnosed with AML and more than 11,300 will die from the disease in 2023.

Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Retrieved on: 
Monday, June 12, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Neutropenia, FACIT, RBC, TET2, University, MOA, Telomerase, ESA, Reverse transcriptase, TI, Erythropoiesis-stimulating agent, Chromosome, Bone marrow, Neuropsychological test, Mutation, TA, Publication, MF, VAF, MDS, ASXL1, Patient, Risk, Anemia, EHA, Therapy, Biology, University of Florence, Cochran–Mantel–Haenszel statistics, Gene, Thrombocytopenia, News, IPSS, Fatigue, Disease, Silviculture, Medical device, Pharmaceutical industry, Nursing, DNMT3A, SF3B1, Imetelstat

This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.

Key Points: 
  • This is the first Phase 3 trial we know of to show an improvement in fatigue in lower risk MDS patients,” stated Dr. Platzbecker.
  • For patients treated with imetelstat, there was a numerically higher percentage of patients reporting any episode of sustained meaningful improvement in fatigue.
  • Further, patients receiving imetelstat experienced a shorter median time to first sustained clinically meaningful improvement in fatigue vs placebo (28.3 vs 65.0 weeks).
  • In addition to these IMerge Phase 3 presentations, Geron collaborators presented a translational analysis from a subset of IMerge Phase 2 patients, as well as imetelstat myelofibrosis (MF) pre-clinical results.

Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress

Retrieved on: 
Monday, June 12, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Paroxysmal nocturnal hemoglobinuria, Consultant, Pharmacokinetics, Society for Integrative Oncology, Haematopoietic system, Teaching hospital, Congress, Corporation, MD, Royal College of Pathologists, EHA, PNH, Patient, Pharmaceutical industry, Bachelor of Medicine, Bachelor of Surgery

Omeros Corporation (Nasdaq: OMER) today announced that the slides presented yesterday in the “late-breaker” session at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany are now available on Omeros’ website .

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced that the slides presented yesterday in the “late-breaker” session at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany are now available on Omeros’ website .
  • The presentation, which details data from a pre-specified interim analysis from the ongoing Phase 1b clinical trial of Omeros’ lead MASP-3 inhibitor OMS906 in complement-inhibitor-naïve adults with paroxysmal nocturnal hemoglobinuria (PNH), was identified by EHA’s Scientific Program Committee as one of the top five late-breaking submissions and selected for oral presentation.
  • Also available on Omeros’ website is a second presentation at EHA – Alternative Pathway MASP-3 Inhibitor OMS906: Results from a First-in-Man Phase 1 Study in Healthy Subjects and Study Design of Two Ongoing Clinical Trials in Patients with PNH – by Morag Griffin, MBChB, FRCPath, Consultant in Haematology of St. James University Teaching Hospital, Leeds, United Kingdom.
  • This poster presentation describes findings from a single-ascending dose study evaluating OMS906 safety, pharmacokinetics and pharmacodynamics in healthy subjects.

Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results in an Oral Presentation at the EHA 2023 Congress

Retrieved on: 
Monday, June 12, 2023
Survivor, EBMT, Radiation, SNMMI, European Hematology Association, Survival, OS, Bone marrow, BMT, HSCT, DCR, TCT, Congress, AML, Patient, EHA, CR, EFS, Haematopoietic system, Transplant, NYSE, Pharmaceutical industry, Actinium

NEW YORK, June 12, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announced positive SIERRA trial results in an oral presentation at the European Hematology Association 2023 Congress (EHA) in Frankfurt, Germany on June 10.

Key Points: 
  • NEW YORK, June 12, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, announced positive SIERRA trial results in an oral presentation at the European Hematology Association 2023 Congress (EHA) in Frankfurt, Germany on June 10.
  • "We are honored to have been accepted for an oral presentation at EHA," said Sandesh Seth, Chairman and Chief Executive Officer.
  • The majority of patients who achieved dCR are long term survivors, in whom OS and EFS was significant.
  • Iomab-B based conditioning was well-tolerated and provided access to HSCT with curative potential in a vulnerable patient population traditionally not considered eligible for HSCT.

Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2023 Hybrid Congress

Retrieved on: 
Monday, June 12, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Abstract, Rituximab, PCNSL, European Hematology Association, DLBCL, Glucocorticoid, Platelet, Lymphoma, Sequence, ITP, Trae Waynes, SSE, Clinical research associate, HKEX, Patient, Randomness, EHA, IVIG, GC, Primary central nervous system lymphoma, ORR, Safety, Medical imaging

Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2023 Hybrid Congress.

Key Points: 
  • Data of InnoCare’s (HKEX: 09969; SSE: 688428) robust pipelines were presented at the European Hematology Association (EHA) 2023 Hybrid Congress.
  • As of cut-off date on 6 Feb 2023, 33 patients were enrolled.
  • Both 50mg QD and 30mg QD of orelabrutinib were safe in the treatment of patients with ITP.
  • Among the 22 patients with previous response to GC or IVIG, 75.0% at the 50mg arm achieved the primary endpoint.

Innovent Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting

Retrieved on: 
Monday, June 12, 2023
Lymphoma, Hodgkin lymphoma, Lymphocyte, Senior, DCR, Sichuan University, Toxicity, Immunotherapy, Incidence, HKEX, HIV disease progression rates, Patient, Anemia, Ophthalmology, CEST, EHA, Hospital, European Society for Medical Oncology, PD-1, Death, PD-L1, ORR, Autoimmunity, Safety, Pharmaceutical industry, Palladium, Center for Innovative Phage Applications and Therapeutics

The EHA Annual Meeting was held in Frankfurt, Germany, from June 8 to 15, 2023.

Key Points: 
  • The EHA Annual Meeting was held in Frankfurt, Germany, from June 8 to 15, 2023.
  • Eligible patients receive IBI322 (45 mg/kg intravenous Q2W) until unacceptable toxicity or disease progression, or up to 24 months.
  • Overall, IBI322 monotherapy showed promising anti-tumor efficacy with a manageable safety profile in anti-PD-1 or PD-L1 treatment-resistant classical Hodgkin lymphoma patients.
  • IBI322 has the potential to be an effective treatment option for the treatment of immunotherapy-resistant classical Hodgkin lymphoma and other types of lymphoma to meet the unmet clinical needs. "

Kura Oncology Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib at 2023 European Hematology Association (EHA) Congress

Retrieved on: 
Sunday, June 11, 2023
Postcholecystectomy syndrome, Menin, Continuity, Venetoclax, Crystal structure, Cancer, Mutation, Massachusetts General Hospital, Kura, MEN1, Acute myeloid leukemia, Congress, Mixed-phenotype acute leukemia, AML, Dor, Patient, KURA, EHA, IDH, FLT3, SCT, CRi, Hospital, Poster, Safety, Disease, Pharmaceutical industry

The updated clinical data are being featured during a late-breaking oral session today at the 2023 European Hematology Association (EHA) Annual Congress in Frankfurt, Germany.

Key Points: 
  • The updated clinical data are being featured during a late-breaking oral session today at the 2023 European Hematology Association (EHA) Annual Congress in Frankfurt, Germany.
  • Notably, 33% (2/6) of patients with FLT3 co-mutations and 50% (4/8) of patients with IDH co-mutations achieved a CR on ziftomenib.
  • Two patients underwent a stem cell transplant (SCT) and remain in remission as of the data cutoff, including one on post-SCT ziftomenib maintenance therapy.
  • “The clinical data presented today continue to demonstrate the ability of ziftomenib to drive durable responses as a monotherapy in heavily pretreated patients with NPM1-mutant AML.

Gracell Biotechnologies Presents Longer-Term Results for FasTCAR-T GC012F in B-Cell Non-Hodgkin’s Lymphoma at EHA2023, Highlighting 100% Overall Response Rate

Retrieved on: 
Saturday, June 10, 2023
IIT, CD19, SCR, European Hematology Association, CRS, DLBCL, B-cell maturation antigen, NHL, Cancer, SLE, B-cell lymphoma, MRD, Congress, Patient, Graceling, SAN, Autoimmune disease, Cytokine release syndrome, EHA, CR, Phenotype, ORR, BCMA, Safety, April 12, Vaccine, Pharmaceutical industry, Tanning (leather), Medical imaging, RRMM

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, June 10, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today presented longer-term follow-up data from a first-in-human study evaluating GC012F, a CD19 and B-cell maturation antigen (BCMA) dual-targeted autologous CAR-T therapeutic candidate, in patients with relapsed/refractory B-cell non-Hodgkin’s Lymphoma (r/r B-NHL) as an oral presentation (abstract #S234) at the European Hematology Association (EHA2023) Congress.

Key Points: 
  • GC012F is manufactured through a novel next-day FasTCAR process and demonstrated a younger phenotype of CAR-T cells and highly effective tumor killing activity in preclinical animal models.
  • In the single-arm, open label investigator-initiated trial (IIT), nine r/r B-NHL patients were enrolled and treated with GC012F, and completed at least three months of follow-up.
  • All patients’ lymphoma samples expressed CD19, and samples from seven out of eight tested patients expressed BCMA.
  • GC012F also continued to show a favorable safety profile:
    Cytokine release syndrome (CRS) was mostly Grade 1 (56%; 5/9).

Aptose Presents Highlights from Clinical Update

Retrieved on: 
Saturday, June 10, 2023
VEN, European Hematology Association, APS, SYK, JAK, TUS, DLT, G1, Acute myeloid leukemia, MDS, US, AML, Patient, SAN, EHA, CR, FLT3, TSX, Infrared spectroscopy correlation table, Gene family, FDA, G3, International Congress on Tuberculosis, Venetoclax, US FDA, Pharmaceutical industry

SAN DIEGO and TORONTO, June 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today released highlights from a clinical update event held today, June 10, 2023, in conjunction with EHA 2023 International Congress of the European Hematology Association in Frankfurt, Germany. The event included an up-to-date review of clinical data for Aptose’s two investigational products under development for hematologic malignancies: tuspetinib, an oral, myeloid kinase inhibitor in the Phase 1/2 APTIVATE trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. The webcast of the presentation is available on Aptose’s website here.

Key Points: 
  • The webcast of the presentation is available on Aptose’s website here .
  • Aptose provided updated clinical findings with tuspetinib, a potent suppressor of FLT3, SYK, JAK 1/2, mutant forms of cKIT, and the RSK1/2 kinases operative in AML:
    Completed tuspetinib dose escalation and dose exploration Phase 1/2 trial in 77 R/R AML patients.
  • Tuspetinib is being administered as a monotherapy and as a combination doublet with tuspetinib + venetoclax (TUS/VEN), and enrollment has been brisk.
  • 50mg G3 formulation with continuous dosing achieves roughly equivalent PK profile as 900mg original G1 formulation.

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Retrieved on: 
Saturday, June 10, 2023
Graft-versus-host disease, Royal Melbourne Hospital, CD19, European Hematology Association, CRS, ICML, Lymphoma, NHL, Histology, NK, Toxicity, CAR, Asilomar International Conference on Climate Intervention Technologies, Patient, Mantle cell lymphoma, SAN, The Retreat, EHA, Biology, MCL, Conference, Neurotoxicity, Pharmaceutical industry, Lead

SOUTH SAN FRANCISCO, Calif., June 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced presentations highlighting preliminary data based on a November 2022 data cut-off from its Phase 1 dose escalation clinical trial of NKX019 at two scientific conferences: the European Hematology Association (EHA) 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma (17-ICML).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., June 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced presentations highlighting preliminary data based on a November 2022 data cut-off from its Phase 1 dose escalation clinical trial of NKX019 at two scientific conferences: the European Hematology Association (EHA) 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma (17-ICML).
  • NKX019 is an allogeneic, off-the-shelf NK cell therapy candidate derived from healthy donors and engineered to target CD19.
  • The presentations will ensure that the broader clinical and academic community has the opportunity to assess the NKX019 clinical data in a peer-reviewed format.
  • Nkarta plans to provide an update from the NKX019 program, including data from dose expansion cohorts, in 2023.